Medicago to present at the U.S. Department of Health and Human Services' Global Health Security Initiativ...(oduction time frame has the potential to...)

Date:11/4/2009

oduction time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release

SOURCE Medicago Inc.

'/>"/>

SOURCE Medicago Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
2. Medicago begins human clinical testing with its avian flu pandemic vaccine
3. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
4. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
5. Medicago succesfully expresses VLP antigen for A H1N1 strain
6. Medicago initiates work on Swine Flu strain
7. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
8. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Additional Data From Fidaxomicins Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
11. ViroPharma to Present at Three November Healthcare Conferences